While we are currently focusing our internal efforts on the development of personalized cancer vaccines, we have demonstrated that our proprietary ATLASTM antigen identification platform can be used across a broad range of disease applications and are seeking partners to realize the full potential of ATLAS in the following antigen discovery areas:
- Tumor-associated antigen (TAA) Programs:
- Profiling T cell responses to known and novel TAAs to enable the development of diagnostic tools, prognostic/companion diagnostic tools for infectious diseases and cancer
- TAA identification for development of cancer vaccines
- Epstein-Barr Virus (EBV)-related cancers:
- Genocea has demonstrated the feasibility of utilizing the ATLAS platform to characterize the T cell responses to EBV in a pilot screening campaign. Results of these efforts were presented in May 2017 at the AAI IMMUNOLOGY conference.
- EBV is a human herpesvirus that infects about 95% of the population. More recently, the virus has been associated with several types of cancer, notably Burkitt’s and Hodgkin lymphomas, gastric and nasopharyngeal carcinoma, and post-transplant lymphoproliferative disease. Thus, understanding and exploiting the immune responses to the virus provides a unique opportunity to create novel vaccine candidates that could impact both infectious disease and cancer.
- US Oncology Research: In December 2016, we announced a collaboration with US Oncology Research, one of the USA's largest research programs specializing in oncology clinical trials, to screen the T cell responses of cancer patients with solid tumors who will be treated with checkpoint inhibitors against the complete repertoire of patient-specific putative cancer neoantigens. The objective of the collaboration is to use ATLAS to further Genocea's expertise in identifying signatures of T cell responses in cancer patients and to discover new T cell cancer vaccine antigens.